Virax Biolabs GroupVRAX
13F holders, Q2 2026 (June 30)2holders
$2.94avg. 13F price*
At the end of Q2 2026, 2 institutions reported holding Virax Biolabs Group Ltd. (VRAX) in their 13F filings. The largest holders were Jane Street Group, LLC ($78K) and UBS Group AG ($12).
- Company
- Virax Biolabs Group Ltd.
- CUSIP
- G9495L133
- Latest filing quarter
- Q2 2026
Total Exit/New Position Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $78K |
| Exits | 0 | $0 |
Ownership 2 holders
| Jane Street Group, LLC | 0.00% | New | 26,385 | $78K |
| UBS Group AG | 0.00% | New | 4 | $12 |
"% of holder's portfolio" is VRAX's weight in each manager's 13F, not the share of Virax Biolabs Group Ltd. the manager owns.